Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celera wins clearance for genotyping software
The ViroSeq HIV-1 genotyping system is said to be designed to detect mutations in the HIV-1 viral genome that confer drug resistance, and as such, is used as
The ViroSeq HIV-1 genotyping system is said to be designed to detect mutations in the HIV-1 viral genome that confer drug resistance, and as such, is used as
Abraxane is now available in India as a single-use 100mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). In October 2007, Abraxane was approved by
The transaction is expected to complete by early August, 2008. The financial details of the agreement were not disclosed. Daiichi Sankyo said that the transaction may affect about
The lead investors were CHL Medical Partners and Foundation Medical Partners and were joined in the round by previous investors Aweida Venture Partners and DFJ Mercury. In connection
In December 2007, Lilly and Galapagos initiated a program to develop new medicines for the treatment of osteoporosis. The agreement provides Lilly access to 12 of Galapagos’s novel
This follows on from the completion of several oral feasibility studies combining Merrion’s Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation
Biovest reported on two clinically relevant data points – overall median disease-free survival data as measured up to 80 months; and disease-free survival data on these same patients
The Mindset-01 Phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 (dirucotide) in patients with relapsing-remitting multiple sclerosis. The fifteen month trial
Using the next-generation sequencing technology of 454 Sequencing and high-density arrays of Roche NimbleGen, the Oxford Biomedical Research Centre (BRC) will work on improved solutions for the analysis
The trial observations included an approximate 40% reduction in mortality for adenocarcinoma patients receiving Tavocept. The percentage of adenocarcinoma patients in the Tavocept group who were alive after